Eric d'Esparbes
2022 - BIORA THERAPEUTICS
In 2022, Eric d'Esparbes earned a total compensation of $1.7M as EVP, Chief Financial Officer at BIORA THERAPEUTICS, a 5% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $146,003 |
|---|---|
| Option Awards | $576,680 |
| Salary | $486,130 |
| Stock Awards | $450,998 |
| Other | $19,773 |
| Total | $1,679,584 |
d'Esparbes received $576.7K in option awards, accounting for 34% of the total pay in 2022.
d'Esparbes also received $146K in non-equity incentive plan, $486.1K in salary, $451K in stock awards and $19.8K in other compensation.
Rankings
In 2022, Eric d'Esparbes' compensation ranked 2,028th out of 5,760 executives tracked by ExecPay. In other words, d'Esparbes earned more than 64.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,028 out of 5,760 | 65th |
Division Manufacturing | 1,086 out of 3,136 | 65th |
Major group Chemicals And Allied Products | 464 out of 1,422 | 67th |
Industry group Drugs | 426 out of 1,323 | 68th |
Industry Pharmaceutical Preparations | 310 out of 969 | 68th |
Source: SEC filing on April 27, 2023.
d'Esparbes' colleagues
We found two more compensation records of executives who worked with Eric d'Esparbes at BIORA THERAPEUTICS in 2022.
News
BIORA THERAPEUTICS CEO Adi Mohanty's 2023 pay slips 11% to $3.1M
April 24, 2024
BIORA THERAPEUTICS CEO Adi Mohanty's 2022 pay falls 65% to $3.5M
April 27, 2023
BIORA THERAPEUTICS CEO Adi Mohanty receives $10M in 2021
April 28, 2022
BIORA THERAPEUTICS CEO Harry Stylli's 2020 pay jumps 1,357% to $5.8M
April 15, 2021
Innoviva CEO Michael Aguiar's 2018 pay slips 11% to $3.7M
March 13, 2019